Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation

Blood Cancer J. 2021 Apr 29;11(4):80. doi: 10.1038/s41408-021-00471-x.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Hematopoietic Stem Cell Transplantation* / methods
  • Humans
  • Leukemia, Myeloid, Acute / diagnosis*
  • Leukemia, Myeloid, Acute / therapy*
  • Middle Aged
  • Neoplasm, Residual / diagnosis*
  • Prognosis
  • Progression-Free Survival
  • Retrospective Studies
  • Transplantation, Homologous / methods
  • Young Adult